- Molecular NameLamotrigine
- SynonymGW 273293; Lamotrigina [Spanish]; lamotrigine; Lamotriginum [Latin]
- Weight256.096
- Drugbank_IDDB00555
- ACS_NO84057-84-1
- Show 2D model
- LogP (experiment)1.497
- LogP (predicted, AB/LogP v2.0)2.12
- pka5.7
- LogD (pH=7, predicted)2.11
- Solubility (experiment)0.17 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-2.4
- LogSw (predicted, AB/LogsW2.0)0.08
- Sw (mg/ml) (predicted, ACD/Labs)1.01
- No.of HBond Donors4
- No.of HBond Acceptors5
- No.of Rotatable Bonds1
- TPSA90.71
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn anticonvulsant drug used in the treatment of epilepsy and bipolar disorder. For epilepsy it is used to treat partial seizures, primary and secondary tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome. Lamotrigine also acts as a mood stabilizer.
- Absorption_value98.0
- Absorption (description)Lamotrigine is readily and virtually completely absorbed, reaching peak concentrations in approx. 1.5 to 5 h.
- Caco_2N/A
- Bioavailability97.6
- Protein binding56.0
- Volume of distribution (VD)0.87~1.2 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmLamotrigine is eliminated primarily by glucuronidation. The parent-metabolite pair may undergo enterohepatic recycling.
- Half life24~35 h
- ExcretionApprox. 2% is eliminated in faeces. The amount of unchanged drug excreted is 30% greater in Gilbert’s Syndrome.
- Urinary Excretion10
- Clerance0.38~0.61 ml/min/kg
- ToxicityNo serious toxicity in a patient who took 1.35 g of lamotrogine and was subsequently treated with gastric lavage and activated charcoal [N.A. Buckley et al.,Lancet,1993, 342, 1552–1553]. Similarly a patient who ingested between 4 and 5 g was admitted to hospital with coma which lasted 8 to 12 h followed by recovery over the next 2 to 3 days. Another patient who ingested 5.6 g was found unconscious and recovered after treatment with activated charcoal and sleeping for 16 h.
- LD50 (rat)LD50=250 (mg/kg)
- LD50 (mouse)LD50=250 (mg/kg)